Physician profile
Robert M Currier
NPI 1093717191
$3,504.07
in general payments reported to CMS, 2019-2025
19 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $204 · 2021: $205 · 2022: $389 · 2023: $154 · 2024: $417 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,717.69 | 2019-2023 | Tecnis Simplicity |
| New World Medical,INC. | $240.17 | 2021-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Mallinckrodt Enterprises LLC | $219.33 | 2019 | |
| Abbvie INC. | $199.24 | 2022-2023 | Durysta |
| Mallinckrodt Hospital Products INC. | $179.39 | 2020-2021 | |
| Astellas Pharma US INC | $178.17 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $175.99 | 2023-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $144.41 | 2021-2022 | |
| Alcon Vision LLC | $69.53 | 2023-2025 | Hydrus Microstent, Clareon |
| Bausch & Lomb Americas INC. | $62.24 | 2022 | |
| Biotissue Holdings INC. | $54.01 | 2019-2022 | |
| Biogen, INC. | $49.08 | 2022 | |
| Pfizer INC. | $44.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.44 | 2024 | |
| Dompe US, INC. | $37.49 | 2019-2024 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $34.94 | 2024-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $20.19 | 2025 | Xdemvy |
| Amgen INC. | $18.17 | 2025 | Tepezza |
| Glaukos Corporation | $16.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Currier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.